APA (7th ed.) Citation

Jung, O., Soto, A., Wolfe, A. L., & Mahajan, S. S. (2025). Daraxonrasib, a pan-RAS inhibitor, selectively inhibits osteosarcomas with activated KRAS by halting AKT signaling and matrix metalloprotease activity. PLoS ONE, 20(8), 1. https://doi.org/10.1371/journal.pone.0329946

Chicago Style (17th ed.) Citation

Jung, Okkeun, Angelene Soto, Andrew L. Wolfe, and Shahana S. Mahajan. "Daraxonrasib, a Pan-RAS Inhibitor, Selectively Inhibits Osteosarcomas with Activated KRAS by Halting AKT Signaling and Matrix Metalloprotease Activity." PLoS ONE 20, no. 8 (2025): 1. https://doi.org/10.1371/journal.pone.0329946.

MLA (9th ed.) Citation

Jung, Okkeun, et al. "Daraxonrasib, a Pan-RAS Inhibitor, Selectively Inhibits Osteosarcomas with Activated KRAS by Halting AKT Signaling and Matrix Metalloprotease Activity." PLoS ONE, vol. 20, no. 8, 2025, p. 1, https://doi.org/10.1371/journal.pone.0329946.